SELLAS Life Sciences Group, Inc (SLS) insider trading
Every open-market stock purchase and sale by SELLAS Life Sciences Group, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $101K over the last 12 months (1 buy).
- Last insider buy: Katherine Bach Kalin (Director), $101K, 10 months ago.
Last 12 months: insiders bought $101K (1 buy) and sold $0 (0 sales). Last close $7.98 on Jun 7, 2026.
Recent SLS insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 16, 2026 | Angelos M. Stergiou (CEO) | Bought (not open market) | — |
| Jan 7, 2026 | Robert L Van Nostrand (Director) | Bought (not open market) | — |
| Jan 7, 2026 | David A Scheinberg (Director) | Bought (not open market) | — |
| Jan 7, 2026 | Jane Wasman (Director) | Bought (not open market) | — |
| Jan 7, 2026 | John Thomas Burns (CFO) | Bought (not open market) | — |
| Jan 7, 2026 | Dragan Cicic (C-suite exec) | Bought (not open market) | — |
| Jan 7, 2026 | John Varian (Director) | Bought (not open market) | — |
| Jan 7, 2026 | Katherine Bach Kalin (Director) | Bought (not open market) | — |
| Dec 3, 2025 | Angelos M. Stergiou (CEO) | Sold (not open market) | $281K |
| Dec 3, 2025 | Dragan Cicic (C-suite exec) | Sold (not open market) | $95.7K |
| Dec 3, 2025 | John Thomas Burns (CFO) | Sold (not open market) | $87.9K |
| Nov 19, 2025 | Katherine Bach Kalin (Director) | Bought | $101K |
Who's trading SLS
- Angelos M. Stergiou, CEO: other filings, last Jun 16, 2026
- Dragan Cicic, C-suite exec: other filings, last Jan 7, 2026
- Katherine Bach Kalin, Director: bought $101K (1 buy), last Jan 7, 2026
- David A Scheinberg, Director: other filings, last Jan 7, 2026
- Jane Wasman, Director: other filings, last Jan 7, 2026
- John Varian, Director: other filings, last Jan 7, 2026
- John Thomas Burns, CFO: other filings, last Jan 7, 2026
- Robert L Van Nostrand, Director: other filings, last Jan 7, 2026
Get free alerts when an insider at SELLAS Life Sciences Group, Inc files a new trade →